{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:13:47Z","timestamp":1765728827044,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bpobgyn.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T23:55:27Z","timestamp":1644278127000},"page":"203-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"PB","title":["Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers"],"prefix":"10.1016","volume":"85","author":[{"given":"Juan-Enrique","family":"Schwarze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Iniesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edel","family":"Falla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasily","family":"Lukyanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"de Agustin Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"D\u00b4Hooghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Matorras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2022.01.011_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The development of gonadotropins for clinical use in the treatment of infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front Endocrinol"},{"author":"EMA","key":"10.1016\/j.bpobgyn.2022.01.011_bib2"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.01.011_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12958-021-00727-y","article-title":"Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F(R)) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis","volume":"19","author":"Chua","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2022.01.011_bib6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14712598.2014.925872","article-title":"Biosimilar recombinant follicle stimulating hormones in infertility treatment","volume":"14","author":"Santi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.01.011_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12958-016-0164-y","article-title":"Safety and efficacy of Ovaleap(R) (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study","volume":"14","author":"Strowitzki","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"year":"2014","series-title":"Bemfola (follitropin alfa) [assessment report]","key":"10.1016\/j.bpobgyn.2022.01.011_bib9"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.01.011_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.rbmo.2015.01.005","article-title":"A\u00a0multi-centre phase 3 study comparing efficacy and safety of Bemfola((R)) versus Gonal-f((R)) in women undergoing ovarian stimulation for IVF","volume":"30","author":"Rettenbacher","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.bpobgyn.2022.01.011_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejogrb.2019.07.032","article-title":"A\u00a0multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha","volume":"241","author":"Barakhoeva","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"10.1016\/j.bpobgyn.2022.01.011_bib12","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.18632\/aging.102919","article-title":"Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in\u00a0vitro fertilization-embryo transfer","volume":"12","author":"Hu","year":"2020","journal-title":"Aging"},{"issue":"11","key":"10.1016\/j.bpobgyn.2022.01.011_bib13","first-page":"1096","article-title":"A\u00a0cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain","volume":"21","author":"Gizzo","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.01.011_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.09.659","article-title":"Budget impact analysis of the introduction of biosimilars in A Belgian tertiary care hospital: a simulation","volume":"19","author":"Claus","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.bpobgyn.2022.01.011_bib15","first-page":"1","article-title":"A\u00a0cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective","author":"Grynberg","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.bpobgyn.2022.01.011_bib16","first-page":"1","article-title":"The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature","author":"Goldstajn","year":"2021","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.bpobgyn.2022.01.011_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/IJWH.S193048","article-title":"A\u00a0cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany","volume":"11","author":"Xue","year":"2019","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.bpobgyn.2022.01.011_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/IJWH.S118687","article-title":"A\u00a0cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility","volume":"8","author":"Gizzo","year":"2016","journal-title":"Int J Womens Health"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.01.011_bib19","doi-asserted-by":"crossref","first-page":"A736","DOI":"10.1016\/j.jval.2015.09.2820","article-title":"Biossimilars, are they really cost saving? The case of recombinant human follicle stimulating hormone in Portugal","volume":"18","author":"Silverio","year":"2015","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.01.011_bib20","doi-asserted-by":"crossref","first-page":"A402","DOI":"10.1016\/j.jval.2016.09.323","article-title":"Cost-effectiveness of recombinant human follicle stimulating hormone biosimilars in Portugal","volume":"19","author":"Silverio","year":"2016","journal-title":"Value Health"},{"year":"2017","series-title":"Consumer affairs and social welfare and the fertility Spanish society: statistical report of assisted reproductions techniques","key":"10.1016\/j.bpobgyn.2022.01.011_bib21"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.01.011_bib22","doi-asserted-by":"crossref","first-page":"A735","DOI":"10.1016\/j.jval.2015.09.2817","article-title":"A\u00a0cost-effectiveness evaluation comparing biosimilar Bemfola to gonal-F for the treatment of infertility in an Italian contest","volume":"18","author":"Ripellino","year":"2015","journal-title":"Value Health"},{"year":"2017","series-title":"Registro de altas. CIE9 MC \u2013 CMBD 2015","key":"10.1016\/j.bpobgyn.2022.01.011_bib26"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:13:44Z","timestamp":1761498824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693422000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":20,"alternative-id":["S1521693422000207"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.01.011","relation":{},"ISSN":["1521-6934"],"issn-type":[{"type":"print","value":"1521-6934"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}